Last reviewed · How we verify

NCT06735625: AHSPDREP

Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"

Recruiting now NA Last updated 2 April 2025
What this trial tests

NA trial testing Measurement of AHSP concentration in in Relation to Sickle Cell Disease in 100 participants. Currently enrolling.

Timeline
6 March 2025
Primary endpoint
20 March 2026
20 January 2027

Quick facts

Lead sponsorCentre Hospitalier de Saint-Denis
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment100
Start date6 March 2025
Primary completion20 March 2026
Estimated completion20 January 2027
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier de Saint-Denis

Who can join

3 and older, any sex, with in Relation to Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Centre Hospitalier de Saint-Denis trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06735625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing